Seres Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2024: 313.56%

Seres Therapeutics, Inc. Return on Equity (ROE) is 313.56% for the Trailing 12 Months (TTM) ending June 30, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Seres Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2022 was -101.17%, a 16.13% change year over year.
  • Seres Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2021 was -87.12%, a -159.71% change year over year.
  • Seres Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2020 was 145.90%, a -22.51% change year over year.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share